Market Newsdesk

Renesas Launches RX23W Module with Bluetooth for System Control and Wireless Communication on IoT Devices

New Radio Law-Certified Bluetooth Module Combines RX23W MCU, Antenna, and Peripheral Circuits in an Industry-leading Small Package

TOKYO–(BUSINESS WIRE)–
Renesas Electronics Corporation (TSE:6723), a premier supplier of advanced semiconductor solutions, today introduced the RX23W Module with full Bluetooth^® 5.0 Low Energy support for system control and wireless communication on IoT endpoint devices. Featuring the RX23W 32-bit RX MCU supporting fully integrated Bluetooth Low Energy communication, the new RX23W module is equipped with an antenna, oscillator and custom-matched circuit. The new module is certified under Radio Law for multiple countries, including Japan and the United States (Note), and is Bluetooth SIG certified. This eliminates the need for additional RF design work, tuning, or specialized RF knowledge, allowing customers to use the module as it is, shortening new product development time. The very small 6.1 mm x 9.5 mm, 83-pin LGA package makes it possible to design more compact devices with fewer external components, reducing the bill of materials (BOM) cost. This improves the development efficiency of IoT endpoint devices such as home appliance, healthcare and sports and fitness equipment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210406005312/en/

The RX23W MCU incorporated in the new module supports full Bluetooth 5.0 Low Energy communication support including long-range and 2 Mbps data throughput. It delivers excellent communication characteristics, with reception sensitivity level of −105 dBm at 125 kbps. Built around Renesas’ RXv2 CPU core, the RX23W MCU provides outstanding computing performance, operating at a maximum clock frequency of 54 MHz together with outstanding power efficiency, making it ideally suited for system control. The RX23W also incorporates Renesas’ exclusive security function, the Trusted Secure IP (TSIP), that provides robust protection against threats to IoT devices such as eavesdropping, tampering, and viruses. In addition, the RX23W MCU has a rich set of peripheral functions that is indispensable to IoT devices, including touch key, USB, and CAN functions.

“As development cycles for IoT devices become shorter, the development burden increases,” said Sakae Ito, Vice President of IoT Platform Business Division at Renesas. “I am delighted that, as we approach the ten-year mark, a wide range of customers have adopted our RX MCUs. We are pleased we can now announce the release of our first Bluetooth communication module based on the Renesas RX MCU, thereby helping to make the development process more efficient.”

Development Environment

The new RX23W module utilizes the same software development environment used for RX MCUs, which means developers can work on both system and communication control at the same time. Smart Configurator enables developers to employ a GUI to generate driver code for peripheral functions and Bluetooth, as well as configuring pin settings. QE for BLE enables developers to generate programs for custom Bluetooth profiles. The Bluetooth Test Tool Suite provides a GUI that allows developers to perform initial wireless characteristics evaluations and Bluetooth functionality verification. These tools are well suited to the various phases of development, providing support for developers from the initial stages through applied product development, and substantially boosting efficiency.

The RX23W Module can be combined with Renesas’ complementary analog and power offerings to create comprehensive solutions for a variety of applications. These “Winning Combinations” showcase the unique capabilities of the RX23W Module and the breadth and depth of Renesas’ product line up. Applications includes a reference design for a Medical Patch that can monitor body temperature, oxygen saturation (SpO2) and heart rate over a Bluetooth connection using RX23W, and a 48V Mobility Solution that can save the mobility battery status and route history by smartphone connection through RX23W.

Pricing and Availability

The RX23W Module is available at the reference price of US$6.60 per 10,000-unit quantities, and mass production and shipping have already begun. A target board for evaluation is also available at a reference price of US$50 per unit, and it is available starting today. For more information on the Renesas RX23W Module, visit: www.renesas.com/rx23w-module

Note: The RX23W Module is certified under the applicable laws of the United States, Canada, the EU, and Japan.

About Renesas Electronics Corporation

Renesas Electronics Corporation (TSE: 6723) delivers trusted embedded design innovation with complete semiconductor solutions that enable billions of connected, intelligent devices to enhance the way people work and live. A global leader in microcontrollers, analog, power, and SoC products, Renesas provides comprehensive solutions for a broad range of automotive, industrial, infrastructure, and IoT applications that help shape a limitless future. Learn more at renesas.com. Follow us on LinkedIn, Facebook, Twitter, and YouTube.

(Remarks) Bluetooth is a registered trademark of Bluetooth SIG, Inc. All registered trademarks or trademarks are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210406005312/en/

Japan

Kyoko Okamoto

Renesas Electronics Corporation

+ 81-3-6773-3001

[email protected]

KEYWORDS: United States Japan North America Asia Pacific California

INDUSTRY KEYWORDS: Engineering Semiconductor Consumer Electronics Technology Manufacturing Mobile/Wireless Hardware

MEDIA:

Logo

Photo

Renesas RX23W module with Bluetooth for system control and wireless communication (Graphic: Business Wire)

McCormack brings an infusion of capital and more than 30 years of technology experience as former CEO of Forcepoint, interim CEO and Chairman at AppRiver and Fidelis Cybersecurity, and senior leader at Symantec, Sygate, and Cisco

Absolute Software Enables Customers to Identify and Address Potential Endpoint Security Risks With Additional Platform Enhancements

Extends power of Absolute’s Persistence technology to more mission-critical applications, including Lenovo Device Intelligence, ensuring they remain healthy and undeletable

VANCOUVER, British Columbia & SAN JOSE, Calif.–(BUSINESS WIRE)–Absolute Software™ (NASDAQ:ABST) (TSX:ABST), a leader in Endpoint Resilience™ solutions, today announced additional platform enhancements, further enabling customers to swiftly pinpoint and respond to potential endpoint security risks across remote, distributed device fleets.

Anchored by its firmware-embedded position in more than half a billion endpoints, Absolute’s patented Persistence^® technology enables an unbreakable two-way connection to devices, applications and data. Leveraging Absolute’s unparalleled visibility, IT and Security administrators can create custom rules to be alerted to a wide range of device or user-related events, such as IP address changes, removal of device hardware, or the disabling of security controls; take immediate action to freeze or wipe the device, and protect sensitive data; and capture the insights needed to demonstrate timely action was taken.

“The number of endpoint devices operating out of physical reach and off the corporate network has made it more challenging than ever for IT and Security admins to identify where their organization might be most vulnerable or exposed to risk,” said Ameer Karim, Executive VP of Product Management at Absolute. “These platform enhancements signal our ongoing commitment to delivering the visibility, intelligence, and self-healing capabilities our customers need to ensure devices and data remain protected, and critical applications stay healthy and resilient.”

Absolute also announced it is enabling customers to extend the power of Absolute’s persistent, self-healing connection to more mission-critical applications, recently adding support for Lenovo^® Device Intelligence. Through Absolute’s Application Persistence™ service, joint customers can ensure Lenovo Device Intelligence remains active and resilient on every endpoint – and in turn, enable IT to continuously monitor device health and quickly resolve any potential device issues or failures before they materialize.

In addition to Lenovo Device Intelligence, Absolute Resilience™ customers have the ability to persist more than 40 leading security agents, including those from ESET^®, Fortinet^®, Netskope^®, VMware^®, and others. A full list of the currently supported apps that comprise Absolute’s Application Persistence ecosystem can be found here.

Customers who would like to learn more about purchasing Absolute’s Application Persistence service as a standalone add-on to their current product offering should contact their authorized Absolute reseller or an Absolute sales representative.

To learn more about how Absolute’s undeletable defense platform enables always-connected visibility and Self-Healing Endpoint™ security, visit www.absolute.com.

About Absolute Software

Absolute Software is a leader in Endpoint Resilience solutions and the industry’s only undeletable defense platform embedded in over a half-billion devices. Enabling a permanent digital tether between the endpoint and the enterprise who distributed it, Absolute provides IT and Security organizations with complete connectivity, visibility, and control, whether a device is on or off the corporate network, and empowers them with Self-Healing Endpoint security to ensure mission-critical apps remain healthy and deliver intended value. For the latest information, visit www.absolute.com and follow us on LinkedIn or Twitter.

©2021 Absolute Software Corporation. All rights reserved. ABSOLUTE, the ABSOLUTE logo, and PERSISTENCE are registered trademarks of Absolute Software Corporation in the United States and/or other countries. Other names or logos mentioned herein may be the trademarks of Absolute or their respective owners. The absence of the symbols ™ and ^® in proximity to each trademark, or at all, herein is not a disclaimer of ownership of the related trademark.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210406005283/en/

Media Relations

Becki Levine

[email protected]

858-524-9443

Investor Relations

Joo-Hun Kim

[email protected]

212-868-6760

KEYWORDS: United States North America Canada California

INDUSTRY KEYWORDS: Data Management Security Technology Mobile/Wireless Software Networks

MEDIA:

Logo

The report states that “Bond’s loyalty platform, Synapze™, has strong campaign design capabilities and a UI with intuitive workflows…” 

Novo Integrated Sciences Announces Preliminary Revenue and Financial Results of Second Quarter Fiscal Year ‘21

BELLEVUE, Wash.–(BUSINESS WIRE)–
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo Integrated Sciences”), a U.S.-based provider of multidisciplinary primary healthcare in Canada, announced today preliminary revenue and other financial results for its Fiscal Year 2021 second quarter period ended February 28, 2021.

• Revenues for the three months ended February 28, 2021 were $2,075,894, representing a decrease of $352,970, or 14.5%, from $2,428,864 for the same period in 2020. The decrease in revenue is principally due to the relative decrease in patient clinic visits due to the COVID-19 pandemic which had not begun to impact clinic visits during this period in 2020.
• Operating costs for the three months ended February 28, 2021 were $2,077,390, representing an increase of $1,083,618, or 109%, from $993,772 for the same period in 2020. The increase in operating costs is principally due to an increase in amortization of intangible assets, common stock issued for services including services related to our successful uplist to the Nasdaq Capital Markets, salary expense due to hiring of senior level executives, and legal fees related to the Company’s Nasdaq listing and filing of the Company’s registration statement on Form S-3.
• Net loss for the three months ended February 28, 2021 was $1,339,870, representing an increase of $835,386, or 165.6%, from $504,484 for the same period in 2020. The increase in net loss is principally due to a 14.5% decline in revenue and an increase in operating costs related to an increase in amortization of intangible assets, common stock issued for services including services related to our successful uplist to the Nasdaq Capital Markets, salary expense due to hiring of senior level executives, and legal fees related to the Company’s Nasdaq listing and filing of the Company’s registration statement on Form S-3.

Robert Mattacchione, the Company’s CEO and Board Chairman, stated, “With the COVID-19 global pandemic having now impacted and challenged our business for over one year, our entire team has risen to the challenge and shown tremendous flexibility and ability to adapt. While the current environment remains challenging, we believe our financial condition is strong and we look ahead to the remainder of 2021 with optimism and dedication to growth.”

About Novo Integrated Sciences, Inc.

Novo Integrated Sciences, Inc. owns Canadian and U.S. subsidiaries which deliver, or intend to deliver, multidisciplinary primary health care related services and products through the integration of medical technology, advanced therapeutics and rehabilitative science. Our clinicians and practitioners are not authorized to practice primary care medicine and they are not medically licensed to prescribe pharmaceutical based product solutions.

Currently, the Company’s revenue is generated solely through the team of multidisciplinary primary health care clinicians and practitioners from the Company’s subsidiary, Novo Healthnet Limited (“NHL”), providing assessment, diagnosis, treatment, pain management, rehabilitation, education and primary prevention for a wide array of orthopedic, musculoskeletal, sports injury, and neurological conditions across various demographics including pediatric, adult, and geriatric populations through NHL’s 16 corporate-owned clinics, a contracted network of affiliate clinics, and eldercare related long-term care homes, retirement homes, and community-based locations in Canada.

Our specialized multidisciplinary primary health care services include, but are not limited to, physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy (including pre- and post-partum), acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, concussion management and baseline testing, trauma sensitive yoga and meditation for concussion-acquired brain injury and occupational stress-PTSD, women’s pelvic health programs, sports medicine therapy, assistive devices, dietitian, holistic nutrition, fall prevention education, sports team conditioning programs including event and game coverage, and private personal training.

We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity offers an essential solution to the fundamental transformation of healthcare delivery. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective healthcare distribution.

For more information concerning Novo Integrated Sciences, please visit www.novointegrated.com. For more information on NHL, please visit www.novohealthnet.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as “believe,” “intend,” “expect,” “anticipate,” “plan,” “potential,” “continue” or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties are discussed in Novo Integrated Sciences’ filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond Novo Integrated Sciences’ control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Novo Integrated Sciences’ current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Novo Integrated Sciences assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The contents of any website referenced in this press release are not incorporated by reference herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210406005295/en/

Chris David, President

Novo Integrated Sciences, Inc.

[email protected]

(206) 617-9797

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Managed Care General Health Health

MEDIA:

Posted on April 6, 2021 8:03 am

Howard J. Federoff, MD, PhD Appointed Chief Executive Officer of Brooklyn ImmunoTherapeutics, Inc.

Howard J. Federoff, MD, PhD Appointed Chief Executive Officer of Brooklyn ImmunoTherapeutics, Inc.

BROOKLYN, N.Y.–(BUSINESS WIRE)–Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn” or “the Company”), a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced the appointment of Howard J. Federoff, M.D., Ph.D., as Chief Executive Officer and President and a director as of 16 April 2021. Dr. Federoff succeeds Ronald Guido who was serving as Interim CEO and will remain on Brooklyn’s management team as Chief Development Officer.

“Dr. Federoff brings an unwavering focus on the patient as well as an outstanding record of clinical, academic and corporate achievement to Brooklyn ImmunoTherapeutics,” said Charles Cherington, Director of Brooklyn. “Dr. Federoff’s unparalleled record of professional accomplishments and experience will be a tremendous asset to Brooklyn ImmunoTherapeutics as we advance the clinical development of IRX-2 as well as explore potential new opportunities. We look forward to working with Dr. Federoff to bring new treatment options to patients living with cancer and other serious diseases.”

“Brooklyn’s IRX-2 product offers a significant opportunity to improve patient outcomes both as a monotherapy and in combination with other anti-cancer drugs including immune-oncology therapies,” said Dr. Federoff. “My top priorities will be the clinical advancement of IRX-2 in solid tumor indications as well as seeking opportunities to in-license new therapeutic agents that can extend and enhance the lives of patients fighting cancer and other serious diseases. This is an exciting time in oncology drug development and I believe that Brooklyn ImmunoTherapeutics will be a leader in advancing patient care.”

Dr. Federoff is a distinguished professor of neurology at the University of California, Irvine. He is the former CEO of UCI Health, vice chancellor for health affairs and dean of the UCI School of Medicine. Prior to joining UCI Health, Federoff was executive vice president of Health Sciences and executive dean at Georgetown University. Dr. Federoff has published more than 275 peer-reviewed and invited articles, and serves on editorial boards of five journals. He co-founded MedGenesis Therapeutix and Brain Neurotherapy Bio, both advancing therapeutics for neurologic diseases. He became CEO of the regenerative medicine company, Aspen Neuroscience, Inc, in San Diego. Aspen is developing an autologous iPSC drug product for Parkinson’s disease. Dr. Federoff chaired the NIH Recombinant DNA Advisory Committee, the NHLBI Gene Therapy Resource and the Board of the Association of the Academic Health Centers. He has served as an advisor/director for several companies. He is an elected Fellow of the American Association for the Advancement of Science and the National Academy of Inventors. He received his MD, MS and PhD in biochemistry from the Albert Einstein College of Medicine in New York. He completed his residency and clinical and research fellowships at Massachusetts General Hospital and Harvard Medical School.

About Brooklyn ImmunoTherapeutics

Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to advance therapies using leading edge gene editing/cell therapy technology through its option agreement with Factor Bioscience/Novellus.

Brooklyn’s most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.

For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210406005284/en/

Media:

MacDougall

Nicholas Chang

[email protected]

781-235-3060

Investor Relations:

CORE IR

516-222-2560

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Oncology

MEDIA:

Logo

NETSCOUT to Support Enterprises in Their Digital Transformation Journey

WESTFORD, Mass.–(BUSINESS WIRE)–NETSCOUT SYSTEMS, INC., (NASDAQ: NTCT), a leading provider of service assurance, networking, and business analytics, today announced a collaboration with Dell Technologies OEM Solutions to deliver solutions designed for medium-to-large-sized enterprises looking for agile, cost-efficient solutions to address their data center and digital transformation needs.

“We share Dell Technologies’ expertise to bring enterprise customers the I.T. solutions they need to advance their infrastructures and transform their businesses in a hyper-digital world,” stated Michael Szabados, chief operating officer, NETSCOUT. “We provide the visibility required for an exceptional customer experience and the agility to deploy new infrastructures and execute other DX initiatives.”

To initiate the collaboration efforts, NETSCOUT certified Dell Technologies’ OEM PowerEdge servers and PowerSwitch switches to work seamlessly with its nGenius Packet Flow Operating System (PFOS) and InfiniStreamNG (ISNG) software. NETSCOUT will also provide customers and channel partners with a three-year warranty and maintenance agreement for the bundled PFOS solution, which will be sold through a single SKU for easy ordering. The two companies will initially work together to sell these solutions in the U.S. to accommodate organizations that have standardized on Dell Technologies platforms in their data centers and offer new customers a simple, reliable, cost-efficient solution. Plans are in place to extend the solutions offered and expand into international markets soon.

“Customers need expanded capabilities, resources, and choices to transform their businesses for the data era,” said John Green, Dell Technologies Vice President, OEM Solutions – Global Sales Engineering. “We’re looking forward to collaborating with NETSCOUT on cutting-edge integrated solutions that support the complex needs of our enterprise customers.”

About NETSCOUT

NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) helps assure digital business services against disruptions in availability, performance, and security. Our market and technology leadership stems from combining our patented smart data technology with smart analytics. We provide real-time, pervasive visibility and insights customers need to accelerate and secure their digital transformation. Our approach transforms the way organizations plan, deliver, integrate, test, and deploy services and applications. Our nGenius™ service assurance solutions provide real-time, contextual analysis of service, network, and application performance. Arbor Smart DDoS Protection by NETSCOUT products help protect against attacks that threaten availability and advanced threats that infiltrate networks to steal critical business assets. To learn more about improving service, network, and application performance in physical or virtual data centers, or in the cloud, and how NETSCOUT’s performance and security solutions powered by service intelligence can help you move forward with confidence, visit www.netscout.com or follow @NETSCOUT on Twitter, Facebook, or LinkedIn.

©2021 NETSCOUT SYSTEMS, INC. All rights reserved. NETSCOUT, the NETSCOUT logo, Guardians of the Connected World, Adaptive Service Intelligence, Arbor, ATLAS, Cyber Threat Horizon, InfiniStream, nGenius, and nGeniusONE are registered trademarks or trademarks of NETSCOUT SYSTEMS, INC., and/or its subsidiaries and/or affiliates in the USA and/or other countries. Third-party trademarks mentioned are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210406005264/en/

Maribel Lopez

Manager, Marketing & Corporate Communications

+1 781 362 4330

[email protected]

Mena Buscetto

Finn Partners for NETSCOUT

+1 860 326 1698

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Data Management Security Technology Telecommunications Software Networks Internet

MEDIA:

Logo

RMR Mortgage Trust First Quarter 2021 Conference Call Scheduled for Wednesday, May 5th

NEWTON, Mass.–(BUSINESS WIRE)–RMR Mortgage Trust (Nasdaq: RMRM), today announced that it will issue a press release containing its first quarter 2021 financial results after the Nasdaq closes on Tuesday, May 4, 2021. On Wednesday, May 5, 2021 at 10:00 a.m. Eastern Time, President Tom Lorenzini and Chief Financial Officer Doug Lanois will host a conference call to discuss these results.

The conference call telephone number is (877) 270-2148. Participants calling from outside the United States and Canada should dial (412) 902-6510. No pass code is necessary to access the call from either number. Participants should dial in about 15 minutes prior to the scheduled start of the call. A replay of the conference call will be available through 11:59 p.m. on Wednesday, May 12, 2021. To access the replay, dial (412) 317-0088. The replay pass code is 10153760.

A live audio webcast of the conference call will also be available in a listen-only mode on the company’s website, which is located at www.rmrmortgagetrust.com. Participants wanting to access the webcast should visit the company’s website about five minutes before the call. The archived webcast will be available for replay on the company’s website after the call.

RMR Mortgage Trust (Nasdaq: RMRM) is a real estate finance company that originates and invests in first mortgage loans secured by middle market and transitional commercial real estate. RMRM is managed by an affiliate of The RMR Group Inc. (Nasdaq: RMR). Substantially all of RMR’s business is conducted by its majority owned subsidiary, The RMR Group LLC, which is an alternative asset management company with $32 billion in assets under management and more than 30 years of institutional experience in buying, selling, financing and operating commercial real estate. For more information about RMRM, please visit www.rmrmortgagetrust.com.

A Maryland Statutory Trust with transferable shares of beneficial interest listed on the Nasdaq.

No shareholder, Trustee or officer is personally liable for any act or obligation of the Trust.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210406005177/en/

Kevin Barry, Manager, Investor Relations

(617) 658-0776

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: REIT Finance Professional Services Commercial Building & Real Estate Construction & Property

MEDIA:

Logo

Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

Partnership will provide access to Valence’s machine learning platform to accelerate preclinical drug discovery efforts

WILMINGTON, Mass. & MONTREAL–(BUSINESS WIRE)–
Charles River Laboratories International, Inc. (NYSE: CRL) and Valence Discovery today announced the formation of a strategic partnership to provide clients access to Valence’s artificial intelligence platform for molecular property prediction, generative chemistry, and multiparameter optimization.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210406005112/en/

Building on research done by Valence’s founding team at Mila, the world’s largest deep learning research institute, the Valence platform enables the design of small molecule drug candidates in novel regions of chemical space, followed by rapid optimization against project-specific potency, selectivity, safety, and pharmacology criteria. Valence has pioneered the application of few-shot learning in drug design, allowing the company to unlock prediction tasks for which only small amounts of training data are available, overcoming a critical limitation of existing machine learning technologies in drug discovery.

Partnering to Accelerate Discoveries

By combining best-in-class machine learning technologies with Charles River’s end-to-end capabilities, the alliance has the potential to significantly accelerate discovery efforts from hit design through lead optimization.

Through the collaboration, Charles River clients will have the option to access Valence’s platform to support their drug discovery efforts. When taking advantage of this option, clients can expect increased diversity in chemical matter being investigated, in combination with more rapid optimization against complex, project-specific design criteria, ultimately reducing timelines and improving success rates for drug discovery projects.

Approved Quotes

• “This collaboration reflects Charles River’s ongoing commitment to enhancing our portfolio of innovative technology solutions. We look forward to leveraging Valence’s unique platform to improve outcomes for our clients.” – Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services, Charles River
• “The Valence platform offers a step-change improvement over existing de novo design technologies. We’ve been consistently impressed by Valence Discovery’s ability to generate high quality chemical matter that’s readily synthesizable, in novel regions of chemical space, from datasets not otherwise accessible to machine learning methods.” – Grant Wishart, PhD, Director of Computer Aided Drug Design, Charles River
• “We are thrilled to be partnering with Charles River, a global leader trusted by many of the world’s top pharmaceutical and biotech companies. This collaboration is an important step in furthering our mission of empowering every drug discovery scientist with the latest innovations in AI-enabled drug design.”– Daniel Cohen, CEO of Valence Discovery

About Valence’s AI-Enabled Drug Design Platform

The Valence platform expands upon academia-leading research done by the company’s founding team at Mila, the world’s largest deep learning research institute. In particular, Valence has pioneered the application of few-shot learning in drug design, allowing the company to unlock prediction tasks for which only small amounts of training data are available, including novel targets and complex ADME criteria, while also ensuring that AI-generated molecules are of high medicinal chemistry quality and readily synthesizable. In addition, Valence uses active learning and iterative optimization strategies to ensure that only the most information-rich compounds are selected for synthesis, enabling the design of compounds meeting the target potency, selectivity, and ADME criteria in fewer iterations, and with far less data, than otherwise possible.

About Valence Discovery

Valence is committed to unlocking the true potential of deep learning in drug design by unifying best-in-class deep learning technologies with intuitive infrastructure to make these technologies more broadly accessible to R&D organizations of all sizes. Valence’s AI-enabled drug design platform has been extensively validated and is currently being used to identify and design drug candidates in collaboration with industry-leading partners. The company is pioneering the application of few-shot learning in drug design and is developing and deploying novel machine learning methods for molecular property prediction, generative chemistry, and multiparameter optimization. Valence (formerly InVivo AI) was founded in 2018, is advised by deep learning pioneer, Dr. Yoshua Bengio, and is proudly headquartered in Montreal at Mila, the world’s largest deep learning research institute, with an office in Cambridge, Mass. To learn more, please visitwww.valencediscovery.com.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210406005112/en/

Charles River Investor Contact:

Todd Spencer

Corporate Vice President, Investor Relations

+1-781-222-6455

[email protected]

Charles River Media Contact:

Amy Cianciaruso

Corporate Vice President, Public Relations

+1-781-222-6168

[email protected]

Valence Corporate Contact:

Therence Bois

Chief Operating Officer, Valence Discovery

[email protected]

Valence Media Contact:

Jessica Yingling, Ph.D.

Little Dog Communications Inc.

[email protected]

+1-858-344-8091

KEYWORDS: United States North America Canada Massachusetts

INDUSTRY KEYWORDS: Health Medical Devices General Health Research Science Pharmaceutical Biotechnology

MEDIA:

Logo

Logo